Zhang Qing, Liu Kun, Yang Wensheng, Shao Wei, Liu Dan, Lan Haitao, Ji Tianhai
Department of Pathology, Affiliated Chenggong Hospital, Xiamen University.
Chinese People's Liberation Army No. 174 Clinical College, Anhui Medical University, Xiamen.
Appl Immunohistochem Mol Morphol. 2018 Oct;26(9):e93-e100. doi: 10.1097/PAI.0000000000000600.
Many tumors, especially gliomas, contain an isocitrate dehydrogenase (IDH) mutation that can be used for clinical diagnosis and prognosis. Our study aimed to develop a new reliable detection assay for IDH1 and IDH2 mutations for clinical diagnosis based on the allele-specific (AS) coamplification with lower denaturing-polymerase chain reaction (COLD-PCR) and probe melting curve analysis (PMCA). The method includes 3 elements allowing for the sensitive detection of low-abundance mutations: (1) PCR amplification of the target fragments with AS primers; (2) COLD-PCR; and (3) PMCA for differentiating the different mutations after amplification. We conducted a blinded study with 45 paraffin-embedded gliomas specimens and 13 fresh specimens screened for IDH mutations using Sanger sequencing. Concordance between the results of our AS-COLD-PCR/PMCA assay and Sanger sequencing was 100%. Our assay appeared to be superior to direct sequencing with a much higher sensitivity of 0.4% mutations. In summary, our assay is a cost-effective, convenient, and sensitive method for detecting IDH mutations and could be applied in the clinical setting to assess small brain biopsies.
许多肿瘤,尤其是胶质瘤,都含有异柠檬酸脱氢酶(IDH)突变,可用于临床诊断和预后评估。我们的研究旨在基于低变性聚合酶链反应(COLD-PCR)的等位基因特异性(AS)共扩增和探针熔解曲线分析(PMCA),开发一种用于临床诊断的IDH1和IDH2突变可靠检测方法。该方法包含三个要素,可实现对低丰度突变的灵敏检测:(1)使用AS引物对靶片段进行PCR扩增;(2)COLD-PCR;(3)扩增后通过PMCA区分不同突变。我们对45个石蜡包埋的胶质瘤标本和13个新鲜标本进行了盲法研究,使用桑格测序法筛选IDH突变。我们的AS-COLD-PCR/PMCA检测结果与桑格测序结果的一致性为100%。我们的检测方法似乎优于直接测序,其对突变的灵敏度高达0.4%,远高于直接测序。总之,我们的检测方法是一种经济高效、便捷且灵敏的检测IDH突变的方法,可应用于临床以评估小脑活检标本。